Proton Magnetic Resonance Spectroscopy: Applications in Neonatal Medicine

Ashwal, Stephen; Bartnik‐Olson, Brenda; Holshouser, Barbara A.

doi:10.1007/978-1-4419-5864-8_8

Cited by 1 publication

(2 citation statements)

References 159 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The uncoupling of oxidative phosphorylation, in turn, results in a dramatic decrease in ATP concentrations and a concomitant increase in anaerobic metabolism, with a marked increase in lactate production. MRS is a well-established technique for demonstrating energy failure and anaerobic metabolism in neonates with perinatal brain injury [21].…”

Section: Discussionmentioning

confidence: 99%

“…Consequently, the ratio of NAA/Cr is regarded as a metabolic indicator of the functional condition of axons and neurons in the brain; hence, it declines in cases of neuronal or axonal degeneration or malfunction [21]. In this research, peak-area ratios of NAA/Cr and NAA/ Cho in the basal ganglia were substantially reduced in group 1 compared with group 2 and the control group, with statistically insignificant decreased ratios in group 2 in comparison with the control group.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Magnetic resonance spectroscopy and auditory brain-stem response audiometry as predictors of bilirubin-induced neurologic dysfunction in full-term jaundiced neonates

Zidan,

Rowisha,

Nassar

et al. 2023

Eur J Pediatr

View full text Add to dashboard Cite

The purpose of this research was to define the functions of MRS and ABR as predictors of bilirubin-induced neurologic dysfunction (BIND) in full-term neonates who required intervention (phototherapy and/or exchange transfusion). This prospective cohort study was done at the NICU of Tanta University Hospitals over a 2-year duration. Fifty-six full-term neonates with pathological unconjugated hyperbilirubinemia were divided according to MRS and ABR findings into 2 groups: group (1) included 26 cases with mild acute bilirubin encephalopathy (BIND-M score 1–4). Group (2) included 30 cases with neonatal hyperbilirubinemia only. In addition, 20 healthy neonates with similar ages were employed as the controls. When compared to group 2 and the control group, group 1’s peak-area ratios of NAA/Cr and NAA/Cho were found to be significantly reduced (P < 0.05). As compared to group 2 and the control group, group 1’s Lac/Cr ratio was significantly greater (P < 0.05), but the differences were not significant for group 2 when compared to the control group. Waves III and V peak latencies, I–III, and I–V interpeak intervals were significantly prolonged in group 1 in comparison to group 2 and controls (P < 0.05) with no significant difference between group 2 and control group. Conclusion: When the symptoms of ABE are mild and MRI does not show any evident abnormalities, MRS and ABR are helpful in differentiating individuals with ABE from patients with neonatal hyperbilirubinemia. Trial registration: ClinicalTrials.gov, Identifier: NCT06018012. What is Known:• MRS can be used as a diagnostic and prognostic tool for the differential diagnosis of patients with acute bilirubin encephalopathy, from patients with neonatal hyperbilirubinemia What is New:• ABR is a useful diagnostic and prognostic tool in the care and management of neonates with significantly raised bilirubin. It can be used as early predictor of acute bilirubin encephalopathy in the earliest stage of auditory damage caused by bilirubin.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%